SAFETY, PHARMACOKINETIC, BIOMARKER, HISTOLOGIC, AND RECTAL BLEEDING ACTIVITY FOLLOWING TREATMENT WITH THE GUT-TARGETED, PHD-INHIBITOR AND HIF-1? STABILIZER GB004 IN A PHASE 1B TRIAL IN MILD-TO-MODERATE ULCERATIVE COLITIS

William Sandborn  ¹     Brian G. Feagan  ²     Silvio Danese  ³     Alina Jucov  ⁴     B.R. Bhandari  ⁵     Kartik Raghupathi  ⁶     Allan Olson  ⁶     Courtney Van Biene  ⁶     Gregory J. Opiteck  ⁶     Julia Ford  ⁶     Richard Aranda  ⁶     Barrett G. Levesque  ^6    
1 UC San Diego Health System, San Diego, United States
² Robarts Clinical Trials Inc., London, Canada
³ Humanitas Research Hospital, Rozzano, Italy
⁴ ARENSIA Exploratory Medicine GmbH, Dusseldorf, Germany
⁵ Delta Research Partners, Bastrop, United States
⁶ Gossamer Bio, Inc., San Diego, United States

Session
IBD Clinical II

Conference
UEG Week Virtual 2020

Citation
United European Gastroenterology Journal 2020; 8 (Supplement 1)